Next Article in Journal
Routine Neuroimaging in Patients with Stage IV Non-Small Cell Lung Cancer: A Single Center Experience
Previous Article in Journal
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Guidelines

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma

1
Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada
2
Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L7, Canada
3
Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1A1, Canada
4
Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada
5
Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON L8S 4L8, Canada
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1114-1124; https://doi.org/10.3390/curroncol28020107
Received: 16 November 2020 / Revised: 29 January 2021 / Accepted: 6 February 2021 / Published: 1 March 2021
Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types. Methods: Consistent with the Program in Evidence-based Program’s standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers. Results: We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible. View Full-Text
Keywords: clinical practice guideline; consolidation therapy; evidence-based; maintenance therapy; ovarian cancer; systemic therapy clinical practice guideline; consolidation therapy; evidence-based; maintenance therapy; ovarian cancer; systemic therapy
MDPI and ACS Style

Hirte, H.; Yao, X.; Ferguson, S.E.; May, T.; Elit, L. An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. Curr. Oncol. 2021, 28, 1114-1124. https://doi.org/10.3390/curroncol28020107

AMA Style

Hirte H, Yao X, Ferguson SE, May T, Elit L. An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. Current Oncology. 2021; 28(2):1114-1124. https://doi.org/10.3390/curroncol28020107

Chicago/Turabian Style

Hirte, Hal, Xiaomei Yao, Sarah E. Ferguson, Taymaa May, and Laurie Elit. 2021. "An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma" Current Oncology 28, no. 2: 1114-1124. https://doi.org/10.3390/curroncol28020107

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop